Oxfam: Patent laws kill thousands | News | Al Jazeera

Oxfam: Patent laws kill thousands

Oxfam has said that Western nations are preventing poor people in developing countries from getting access to life-saving medicines.

    Thousands of patients in developing countries cannot afford medicine [file]

    A new trade agreement designed to make medicine cheaper by relaxing patent laws was being implemented too slowly, Oxfam and Aids groups said on Tuesday

    Oxfam, a British-based anti-poverty charity, also said that 

    rich nations had taken little or no action towards meeting their obligations under the "Doha Declaration", leaving millions without affordable drugs.

    Steve Cockburn, the Stop Aids campaign co-ordinator, said: "At the time, the Doha Declaration seemed like a great breakthrough for people in poor countries who urgently needed affordable treatment.

    "Sadly, promising words have not translated into life-saving treatments."

    The agreement, signed five years ago, was designed to put patients before profits and allow local pharmaceutical manufacturers to provide cheaper medicine for patients in developing countries.

    Health activists say that access to cheap generic drugs is vital if poor countries are going to put up an effective fight against fatal diseases such as Aids and malaria.

    Doha Declaration

    In 2001 the World Trade Organisation granted a special exemption to allowing countries to put public health ahead of patents within its Trade Related Aspects of Intellectual Property Rights (TRIPS) agreement.
       
    But Oxfam said that rich countries, particularly the US, were bullying developing countries to impose stricter patent rules in order to preserve pharmaceutical monopolies.

    Innovative treatment

    The clash over patents in the developing world has focused attention on a two high-profile cases including a dispute over the cancer drug Glivec, made by Switzerland's Novartis.
       
    An Indian court in January rejected its patent application for Glivec, but Novartis is fighting back, arguing that the principle of intellectual property protection must be protected if innovation is to flourish.
       
    The ruling has minimal commercial significance because 99 per cent of Indian patients are entitled to receive the drug free of charge under a Novartis compassionate use programme.
       
    But Paul Herrling, the company's head of corporate research, told the Reuters Health Summit last week that India risked falling behind China in drug research if it did not shore up its weak patent protection system.

    SOURCE: Aljazeera + Agencies


    YOU MIGHT ALSO LIKE

    Interactive: Coding like a girl

    Interactive: Coding like a girl

    What obstacles do young women in technology have to overcome to achieve their dreams? Play this retro game to find out.

    America's Guns: Secret Pipeline to Syria

    America's Guns: Secret Pipeline to Syria

    How has the international arms trade exacerbated conflict in the Middle East? People and Power investigates.

    I remember the day … I designed the Nigerian flag

    I remember the day … I designed the Nigerian flag

    In 1959, a year before Nigeria's independence, a 23-year-old student helped colour the country's identity.